GSK Shares Slip After $10.6 Billion Nuvalent Buyout

Shares of GSK dropped more than 2% after the British pharmaceutical giant announced it would acquire Boston-based biotech Nuvalent for $10.6 billion. This huge bet on specialized cancer therapies sent ripples through the market.

The all-cash deal prices Nuvalent's shares at $124 each, reflecting a 40% premium over the company's recent closing price and its average over the past month. After accounting for cash on hand, the net price for GSK comes in at $9.4 billion.

GSK's CEO Luke Miels didn't shy away from the deal's size in a media call, pointing out that snagging several clinical-stage products in one move is rare. He expressed confidence that the acquisition was essential and hinted at plans to mitigate associated debt expenses.

At the heart of the acquisition lie three lung cancer drugs: zidesamtinib (NVL-520) and neladalkib (NVL-655), both targeted at non-small cell lung cancer and recognized by the FDA with Breakthrough Therapy and Orphan Drug statuses, with approval target dates set for 2026. A third candidate, NVL-330, is earlier-stage, still in Phase I trials aimed at HER2-altered NSCLC.

Nuvalent's CEO James Porter highlighted GSK's solid commercialization infrastructure as key to bringing these treatments to market effectively. The added pipeline could broaden GSK's reach in oncology treatments significantly.

According to the firm, the acquisition's financial impact will start to reflect in revenues by 2027 and is forecasted to add positively to core operating profits and earnings per share by 2029, once synergy effects and reprioritization benefits kick in.

Miels emphasized that while the deal isn't required for GSK to hit its £40 billion sales ambition by 2031, it's expected to bolster those growth goals. The current 2026 guidance remains intact, signaling no drastic near-term profit hits, though some low-single-digit EPS dilution is anticipated over the next three years.

The company plans to finance the purchase largely via existing and new debt facilities, maintaining a strong investment-grade credit rating and confirming its 70 pence dividend forecast for 2026. Regulatory approval under antitrust laws is still pending, with a formal tender offer and merger slated within the coming weeks.

Market participants are watching the fallout from this bold acquisition with interest, questioning if GSK's premium price will pay off long term amid intensifying competition in the oncology space.